@article{JTD28553,
author = {Aoran Dong and Jiali Zhang and Xiaobin Chen and Xiubao Ren and Xinwei Zhang},
title = {Diagnostic value of ProGRP for small cell lung cancer in different stages},
journal = {Journal of Thoracic Disease},
volume = {11},
number = {4},
year = {2019},
keywords = {},
abstract = {Background: To investigate the roles of gastrin-releasing peptide (ProGRP) in the diagnosis of small cell lung cancer (SCLC).
Methods: We retrospectively analyzed data from 11,206 patients with clinical suspicion of lung cancer from January 1, 2015 to May 31, 2018. ProGRP and neuron-specific enolase (NSE) were detected in peripheral blood, and receiver operating characteristic curve (ROC) was used for analysis.
Results: ROC indicated that the cutoff values of ProGRP and NSE were 66 ng/L and 18 µg/L respectively, and the diagnosis efficacy of ProGRP was greater than that of NSE (sensitivity: 86.5% vs. 78.8%; specificity: 96.5% vs. 86.3%, respectively) in the diagnosis of SCLC. Moreover, the median level of ProGRP in SCLC increased with the accompanying stages (P},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/28553}
}